Sort
8,912 grants matching “sars cov 2”
Diagnosis of MIS-C in febrile children
$1,565,422Audrey Ragan Odom John · Children'S Hosp Of Philadelphia · R33 · FY2023 · HD
Stanford/UNC Biomimetic U19 Research Center
$1,559,276Calvin J Kuo · Stanford University · U19 · FY2021 · AI
Identifying biomarker signatures of prognostic value for Multisystem Inflammatory Syndrome in Children (MIS-C)
$1,558,561Juan C Salazar · Connecticut Children'S Medical Center · R33 · FY2023 · HD
Innate inflammatory responses during pulmonary infections
$1,558,229Katrin Mayer-Barber · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Immunological responses to pan-CoV vaccines
$1,558,161Yoshihiro Kawaoka · University Of Wisconsin-Madison · P01 · FY2023 · AI
A data science approach to identify and manage Multisystem Inflammatory Syndrome in Children (MIS-C) associated with SARS-CoV-2 infection and Kawasaki disease in pediatric patients
$1,558,153Benjamin Barnes · Johns Hopkins University · R33 · FY2023 · HD
Microbial, immune, metabolic perturbations by antibiotics (MIME study)
$1,558,030Martin J Blaser · Rbhs-Robert Wood Johnson Medical School · U01 · FY2020 · AI
Human Biomimetics for Mucosal Infections
$1,557,840Mary Kolb Estes · Baylor College Of Medicine · U19 · FY2022 · AI
Research Initiatives on COVID-19 in the Division of the National Toxicology Program
$1,557,106Brian Berridge · National Institute Of Environmental Health Sciences · ZIA · FY2021 · ES
Standardized Assays for Profiling Antibody Candidates against SARS-CoV2
$1,555,327National Institute Of Allergy And Infectious Diseases · Y01 · FY2020 · AI
Clinical and Informatics Research on Large Clinical Databases
$1,554,491Clement McDonald · National Library Of Medicine · ZIA · FY2021 · LM
Novel Protease Inhibitors as SARS Therapeutics
$1,553,610Michael E. Johnson · University Of Illinois At Chicago · P01 · FY2009 · AI
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
$1,549,397Charles Bix Shoemaker · Tufts University Boston · R01 · FY2025 · AI
NIEHS Gene Editing and Mouse Model (GEMM) Core Annual Report
$1,546,971Manas Ray · National Institute Of Environmental Health Sciences · ZIC · FY2023 · ES
Wastewater Assessment for Coronavirus in Kentucky: Implementing Enhanced Surveillance Technology
$1,546,299Scott M Berry · University Of Kentucky · U01 · FY2022 · DA
CEIRR: COVID-19 Research Activities
$1,545,991Scott Hensley · University Of Pennsylvania · N01 · FY2023 · AI
Protective Genetic Variants for Alzheimer Disease in the Amish - RENEWAL
$1,545,583Jonathan L. Haines · Case Western Reserve University · R01 · FY2025 · AG
Uncovering associations of variant infection with COVID-19 disease severity in children
$1,541,111Charles Yen Chiu · University Of California, San Francisco · R61 · FY2022 · HD
HRS Yrs 29-34: Covid Antibody Revision
$1,538,248David R. Weir · University Of Michigan At Ann Arbor · U01 · FY2021 · AG
Animal models and related services (AMRS) core
$1,538,028Padmini Salgame · Rutgers Biomedical And Health Sciences · UC7 · FY2025 · AI
quantitative CT development and clinical applications
$1,531,012Han Wen · National Heart, Lung, And Blood Institute · ZIA · FY2024 · HL
Biomarker Investigations for Clinical Trials
$1,530,925Liang Cao · Division Of Basic Sciences - Nci · ZIC · FY2021 · CA
mVACS--mRNA Vaccines for C. difficile Suppression
$1,529,954Frederic D Bushman · University Of Pennsylvania · U19 · FY2025 · AI
mVACS--mRNA Vaccines for C. difficile Suppression
$1,529,954Frederic D Bushman · University Of Pennsylvania · U19 · FY2024 · AI
mVACS--mRNA Vaccines for C. difficile Suppression
$1,529,954Frederic D Bushman · University Of Pennsylvania · U19 · FY2023 · AI